Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018;48(1):43-60.
doi: 10.1007/s40005-017-0370-4. Epub 2017 Nov 28.

Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics

Young Hee Choi  1 , Hyo-Kyung Han  1
Affiliations
Review

Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics

Young Hee Choi et al. J Pharm Investig. 2018.

Erratum in

Abstract

Nanomedicines have evolved into various forms including dendrimers, nanocrystals, emulsions, liposomes, solid lipid nanoparticles, micelles, and polymeric nanoparticles since their first launch in the market. Widely highlighted benefits of nanomedicines over conventional medicines include superior efficacy, safety, physicochemical properties, and pharmacokinetic/pharmacodynamic profiles of pharmaceutical ingredients. Especially, various kinetic characteristics of nanomedicines in body are further influenced by their formulations. This review provides an updated understanding of nanomedicines with respect to delivery and pharmacokinetics. It describes the process and advantages of the nanomedicines approved by FDA and EMA. New FDA and EMA guidelines will also be discussed. Based on the analysis of recent guidelines and approved nanomedicines, key issues in the future development of nanomedicines will be addressed.

Keywords: Delivery; Guidelines; Nanomedicines; Pharmacokinetics.

PubMed Disclaimer

Conflict of interest statement

Compliance with ethical standardsThese authors (Young Hee Choi and Hyo-Kyung Han) declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
A proposed new algorithm to assess ADME of nanomedicines
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Arnold J, Kilmartin D, Olson J, Neville S, Robinson K, Laird A. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131:541–560. - PubMed
    1. Asthana A, Chauhan AS, Diwan PV, Jain NK. Poly(amidoamine) (PAMAM) dendritic nanostructures for controlled site-specific delivery of acidic anti-inflammatory active ingredient. AAPS PharmSciTech. 2005;6:E536–E542. - PMC - PubMed
    1. Barenholz Y. Doxil®—the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117–134. - PubMed
    1. Benbrook DM. Biotechnology and biopharmaceuticals: transforming proteins and genes into drugs, 2ndedition. Off Publ Infect Dis Soc Am. 2015;60:331–332.
    1. Berges R, Eligard R. Pharmacokinetics, effect on testosterone and PSA levels and tolerability. Eur Urol Suppl. 2005;4:20–25.

LinkOut - more resources